Zobrazeno 11 - 20
of 38
pro vyhledávání: '"Cornelius Kortsik"'
Autor:
Jürgen Fischer, Monika Serke, Martin Wolf, Alexander Reuss, Niels Reinmuth, Cornelius Kortsik, Philipp A. Schnabel, Petra Neuser, Michael Thomas, Piotr Czapiewski, Matthias Villalobos, Stefan Andreas
Publikováno v:
Medical oncology (Northwood, London, England). 35(7)
Prior studies have demonstrated an association between excision repair cross-complementation group 1 (ERCC1) expression level and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy. The aim
Autor:
Thomas Wehler, Jan Stratmann, Maria Blettner, Cornelius Kortsik, Sebastian Wiesemann, Martin Sebastian, Beatrice Wehler, Susanne Singer, Hubert Wirtz, Roland Buhl, Jessica Peuser, Marlene Hechtner, Martin Eichler, Heinz Schmidberger, Ursula Nestle
Publikováno v:
Psycho-oncology. 27(8)
Autor:
Walburga Engel-Riedel, Christian Schumann, Martin Kohlhaeufl, Claus-Peter Schneider, Martin Reck, Gert Hoeffken, Cornelius Kortsik, Monika Serke, Wolfgang Schuette
Publikováno v:
Lung Cancer: Targets and Therapy
Wolfgang Schuette,1 Claus-Peter Schneider,2,3 Walburga Engel-Riedel,4 Christian Schumann,5,6 Martin Kohlhaeufl,7 Monika Heidi Ursel Serke,8 Gert Hoeffken,9 Cornelius Kortsik,10 Martin Reck11 1Department of Internal MedicineII, Hospital Martha-Maria H
Autor:
Christian Witt, Thomas Acker, Jens Kollmeier, Ernst Müller, Michael Schenk, Martin Wolf, Michael Thomas, Philipp A. Schnabel, Roland Penzel, Jürgen Fischer, Alexander Reuss, Michael Schröder, Cornelius Kortsik, Stefan Andreas, Michael von Eiff, Monika Serke, Matthias Villalobos, Niels Reinmuth, Christian Grah
Publikováno v:
European Respiratory Journal. 46:219-229
Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination comp
Autor:
Martin Schuler, Beatrice Wehler, Kurt Werner Schmid, Martin Sebastian, J. Wohlschläger, Stefan Kasper, Daniela Westerwick, Birgit Gaschler-Markefski, Arno Schad, Gerd Munzert, Martin Werner, Karl Worm, Alicia Morresi-Hauf, Joachim von Pawel, Saskia Ting, Frank Breitenbuecher, Cornelius Kortsik
Background: Polo like kinase 1 (PLK1) is frequently upregulated in tumors and is thus viewed as a promising therapeutic target in various cancers. Several PLK1 inhibitors have recently been developed and clinically tested in solid cancers, albeit wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88233e25fdcedd25c30c20e3ea4c6154
https://www.ncbi.nlm.nih.gov/pubmed/28628916
https://www.ncbi.nlm.nih.gov/pubmed/28628916
Autor:
S. Bohnet, David F. Heigener, Martin Reck, Cornelius Kortsik, Joachim von Pawel, M.v. Eiff, W. Koester, Philipp A. Schnabel, K.M. Deppermann, Michael Thomas, Juergen R. Fischer
Publikováno v:
Lung Cancer. 84:62-66
Background Targeting the epidermal-growth-factor-receptor (EGFR) in non-small cell lung cancer (NSCLC) is an established treatment option with less toxicity compared to conventional chemotherapy. This study was undertaken to determine whether Erlotin
Autor:
Ulrich Gatzemeier, Igor Bondarenko, Yevhen Hotko, Jae Kyung Roh, Christopher Stroh, Cornelius Kortsik, Kenneth J. O'Byrne, Rodryg Ramlau, Carlos H. Barrios, Corinna Eschbach, Robert Pirker, Chih Teng Yu, Armin Schueler, Uwe M. Martens, Luis Paz-Ares, Joachim von Pawel, José Rodrigues Pereira, Ilhan Celik
Publikováno v:
The Lancet Oncology. 12:795-805
Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced n
Autor:
Cornelius Kortsik, Cornelius F. Waller, Martin Reck, Martin Schuler, N. Frickhofen, Martin Sebastian, Gertraud Hanft, Gerd Munzert, Birgit Gaschler-Markefski, Joachim von Pawel, Holger Fritsch
Publikováno v:
Journal of Thoracic Oncology. 5:1060-1067
Objective To investigate the efficacy, safety, and pharmacokinetics of two dosing schedules of BI 2536, a novel polo-like kinase-1 inhibitor, in patients with relapsed stage IIIB/IV non-small cell lung cancer. Methods Ninety-five patients were random
Autor:
Roland Buhl, Cornelius Kortsik, Ignaz Wessler, Björn Hölper, Heinz Kilbinger, Charles James Kirkpatrick
Publikováno v:
Life Sciences. 80:2294-2297
In human airways mucosal mast cells are under the control of inhibitory muscarinic receptors. The described experiments tested, whether the inhibitory potency of two muscarinic receptor agonists (oxotremorine, acetylcholine) becomes impaired in advan
Autor:
Walburga Engel-Riedel, G. Hoeffken, Claus-Peter Schneider, Martin Reck, M. Kohlhaeufl, S Nagel, C. Schumann, Monika Serke, Cornelius Kortsik, W. Schütte, K Reuse
Publikováno v:
Pneumologie. 68